Unknown

Dataset Information

0

A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.


ABSTRACT: OBJECTIVE:To perform a randomized controlled trial of rituximab in patients with hepatitis C virus (HCV)-associated mixed cryoglobulinemic vasculitis. METHODS:We conducted a single-center, open-label, randomized controlled trial of rituximab (375 mg/ m(2) /week for 4 weeks) compared to the best available therapy (maintenance or increase in immunosuppressive therapy) for HCV-associated cryoglobulinemic vasculitis in patients in whom antiviral therapy had failed to induce remission. The primary end point was disease remission at 6 months from study entry. RESULTS:A total of 24 patients were enrolled (12 in each treatment group). Baseline disease activity and organ involvement were similar in the two groups. Ten patients in the rituximab group (83%) were in remission at study month 6, as compared with 1 patient in the control group (8%), a result that met the criterion for stopping the study (P < 0.001). The median duration of remission for rituximab-treated patients who reached the primary end point was 7 months. No adverse effects of rituximab on HCV plasma viremia or on hepatic transaminase levels were observed. CONCLUSION:Rituximab was a well-tolerated and effective treatment in patients with HCV-associated cryoglobulinemic vasculitis in whom antiviral therapy failed to induce remission.

SUBMITTER: Sneller MC 

PROVIDER: S-EPMC3243106 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.

Sneller Michael C MC   Hu Zonghui Z   Langford Carol A CA  

Arthritis and rheumatism 20120301 3


<h4>Objective</h4>To perform a randomized controlled trial of rituximab in patients with hepatitis C virus (HCV)-associated mixed cryoglobulinemic vasculitis.<h4>Methods</h4>We conducted a single-center, open-label, randomized controlled trial of rituximab (375 mg/ m(2) /week for 4 weeks) compared to the best available therapy (maintenance or increase in immunosuppressive therapy) for HCV-associated cryoglobulinemic vasculitis in patients in whom antiviral therapy had failed to induce remission.  ...[more]

Similar Datasets

| S-EPMC5849501 | biostudies-literature
| S-EPMC10648453 | biostudies-literature
| S-EPMC4949984 | biostudies-literature
| S-EPMC5522247 | biostudies-other
| S-EPMC8878349 | biostudies-literature
| S-EPMC10789906 | biostudies-literature
| S-EPMC9305531 | biostudies-literature
| S-EPMC5341185 | biostudies-literature
| S-EPMC9096513 | biostudies-literature
| S-EPMC3510348 | biostudies-literature